CA-HD-MEDICAL-INC
11.1.2021 14:07:39 CET | Business Wire | Press release
At CES’21, HD Medical Inc. today introduces HealthyU™, an intelligent remote patient monitoring device, in response to the ongoing challenges of remote Telehealth, Cardiac Care, and Wellness during the pandemic and beyond.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005444/en/
HealthyU™ is the first home device to provide:
- 7-lead ECG (without wires)
- Heart Sounds with Murmur Analysis
- Lung Sounds
- Heart Rate
- Pulse Oximetry (SpO2 / blood oxygen saturation)
- Temperature
- Respiratory Rate
- Cuffless Blood Pressure Trend
The Future of Telehealth, Home Monitoring, and Wellness
As the medical community seek new ways to deliver care, HealthyU™ takes multiple complex healthcare devices and turns them into one easy-to-use device for the patient and the provider to connect via a simple HD App and HD Cloud Platform for Intelligent Insights, or also with any video conferencing and screen sharing tool for Remote Consultation.
Providers can listen live to the heart and lung sounds using HD Steth™ , HD Medical’s flagship intelligent stethoscope technology, cleared by FDA in July 2020 for Electronic Stethoscope, Phonocardiograph and Electrocardiograph.
Created with and available first to those with cardiac care and monitoring needs, HealthyU™ is available to clinical partners for research and corporate wellness partners seeking employee wellness offerings of this caliber, as well as for Telehealth pilot programs under IRB Protocol in accordance with FDA Regulations. HD Medical will be seeking Emergency Use Authorization from the FDA to make available in the U.S. and enable fully informed at-home doctor-patient visits during the pandemic and beyond.
HD Medical at CES Unveils HealthyU
“I’ve been treating patients remotely for nearly a year now and the pandemic has severely limited my ability to understand my patient’s condition. As we move forward, telehealth represents a paradigm shift in healthcare delivery during the pandemic and beyond. HealthyU will play a critical role and promises to not only save lives but also improve the quality of life for all patients,” said Dr. Nelson B. Schiller, MD, FACC, FRCP, Professor of Medicine & Anesthesia, UCSF.
"HealthyU is one of those rare medical devices that is truly a game changer in patient care. Being so user friendly and clinically sound, this device can be used in many different clinical scenarios and can truly be a lifesaver for multitudes of patients, who have the possibility of obtaining care while at home," said Dr. Shaun Setty, MD of The Larry and Helen Hoag Endowed Chair of Pediatric Cardiovascular Surgery in Los Angeles, CA.
“2020 has put greater emphasis on the need to advance remote patient monitoring technology, which is why we have prioritized bringing integrated sensors and intelligent insights into the home making it easy for patients to use and viable for providers to leverage during care,” said Arvind Thiagarajan, founder and CEO of HD Medical. “HealthyU™ performs wireless ECG outside of the hospital while incorporating auscultation and other important vitals. By simplifying the remote monitoring process, we’ve ensured this technology can be leveraged by anyone that needs it.”
HealthyU is currently intended for investigational use only, not for sale in the United States until after FDA clearance. HD Medical expects that HealthyU will be available for sale in the US by the third quarter of 2021, subject to FDA clearance process, which is being undertaken expeditiously. In the meantime, HealthyU will be available to clinical partners for research and corporate wellness programs, as well as telehealth pilot programs under the IRB protocol in accordance with FDA regulations.
To become a HealthyU™ partner, email info@hdmedicalgroup.com .
About HD Medical, Inc.
HD Medical, Inc. is a Silicon Valley-based innovator of digital health solutions for AI-enabled detection and management of cardiovascular disease (CVD). HD Steth has been awarded FDA clearance (K201299). The company delivers its intelligent cardiac care solutions and products globally to medical professionals and institutions through channel partners. Visit www.HealthyU.ai and www.hdmedicalgroup.com .
Note to editors: HealthyU, HD Steth, HD App, and HD Cloud Platform are registered trademarks of HD Medical, Inc. All other product, service or organization names remain the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005444/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
